8/8/2019 Aqua Bounty Fact Sheet - Corfin

1/1

KeybenefitsofAquAdvantageSalmon: Reducedpressureonwildfishstocks:Byprovidingareadysource

offastergrowingfish,salmongrownfromAquAdvantageeggscan

helpreducepressureonwildfishstockssufferingfromoverfishing

Job creation: Aquaculture provides opportunities for U.S.jobsbypotentiallycontributingtoanewlyreinvigorateddomesticindustry,

asopposedtoimportingsalmonfromotherpartsoftheworld

Economic benefits: Faster growth means a more efficient use ofcapital,reducedfeedcostsandlesstimetomarket

Lower carbon footprint:AquAdvantage salmon aregrown in onshorefacilitiesthatcanbebuiltclosetoconsumermarketswhereas

freshandfrozenfishrequireenergyintensivetransportation

AquaBounty Technologiesisabiotechnologycompany

focused on enhancing productivity in the aquaculture

market.

Its AquAdvantage Salmon product consists of

standardAtlanticsalmoneggs that includeagenefrom

Chinook salmon, which enables the fish to grow to

market size in half the time of conventional Atlantic

salmon.

The product is currently going through the approval

process of the US Food & Drug Administration.

Significantly, the fish wouldbe the first food from a

transgenicanimaltobeapprovedbytheFDA.

The company,under thenameA/FProtein,acquireda

license totheAquAdvantage technology in1996 from

theUniversity ofToronto andMemorialUniversity of

Newfoundland. A/F Protein was separatedThe

AquAdvantage division was separated from the

combined company in 2000 to become AquaBounty

Farms, which was amended to AquaBounty

Technologiesfouryearslater.

AquaBounty is listed on theLondon Stock Exchanges

AIMandisheadquarteredinBoston,USA,with its test

facilitieslocated

on

Prince

Edward

Island,

Canada.

AquaBountyTechnologiesInc.

935MainStreet

Waltham

Massachusetts

MA02451

USA

Tel:+17818997755 Fax:+17818992814

www.aquabounty.com

KeyFinancialsSharePrice(asat19.07.10): 10.25p

MarketCap: 4.38m

ListingonAIM: 20Mar2006

Stocktradingsymbol: ABTX

FTSESector: Pharmaceuticals&Biotechnology

KeyManagement:RonaldL.StotishExecutiveDirector,PresidentandChiefExecutiveOfficerRonald L. Stotish, Ph.D. was appointed an Executive

Director, President and CEO of AquaBounty

Technologies in May 2008. Dr. Stotish joined

AquaBountyTechnologies in2006asVicePresident for

RegulatoryAffairs, andmost recentlywas SeniorVice

President for R&D and Regulatory Affairs. Prior to

joining AquaBounty, Dr. Stotish was Executive Vice

President forR&D atMetaMorphix, Inc.Hebegan his

career

in

research

at

Merck.

Dr.

Stotish

has

degrees

in

biochemistry and over 38 years experience in the

discovery,development, and commercialization ofnew

animalhealthproducts.

DavidA.FrankChiefFinancialOfficerDavid Frank was appointed CFO in October 2007.

PreviouslyheservedasPresidentandGeneralManager

of TekCel LLC, a subsidiary of Magellan Biosciences,

after serving as Magellans CFO since the companys

founding in 2004 and asTekCelsCFO since 2003.Mr.

Frank has over 25 years of financialmanagement

experience, including as CFO of SmartEnergy and

corporatecontrollerforMoldflow.HehasaBSinfinance

andaccounting fromBostonCollegeandanMBA from

BabsonCollege.

Forfurtherinformation:HarryChathli/ClaireNorbury/NeilThapar

CorfinPublicRelationsLtd.

12thFloor,TheBroadgateTower,20PrimroseStreet,

London,EC2A2EW,UnitedKingdom

Tel:+44(0)2075962860 Fax:+44(0)2075962868

www.corfinpr.com

FDAapproval: Completion of all outstanding FDA submissions and requests for

informationin2009

Successful

FDA

inspection

of

the

Companys

production

facility

InMarch 2010, the FDA issued the conclusion of its review of theAAS ClaimValidation study indicating the remaining sections

wouldbeissuedinduecourse

Recently received letters from the Center for Veterinary Medicine(FDA subbody) confirmingAquaBountyhaspassed threeof seven

partsoftheirexaminationoftheapplication

ThecompanybelievesthereviewsfortheremainingfourpartsoftheCVMexaminationareverynearlycompleteandexpecta successful

outcomeinthenearfuture,withtheholdingofaVeterinaryMedical

AdvisoryCommitteemeetingas thenextstep in the formalprocess

fortheFDAapprovaloftheproduct

Commercialmarkettest:

Performance

of

AAS

in

commercial

market

test

met

expectations

Established relationships with producers/authorities in severalcountries who have appropriate production resources and are

interestedintestingtheproduct

R&Dcontinuesonnextgenerationproducts